Psoriasis: from gene to clinic

Date: Nov 30, 2017 - Dec 02, 2017
Organization: International Psoriasis Council, The University of Manchester, St John’s Institute of Dermatology
Location: London, UK
Website: http://psoriasisg2c.com/

Considerable progress has been made over recent years in our understanding of psoriasis at both fundamental basic science and clinical levels. Identification of immunopathological mechanisms that lead to the expression of disease and elucidation of cellular processes which control proliferation and differentiation are integral to the development of new therapies and therapeutic approaches specifically designed for psoriasis. Furthermore, significant progress has been made in understanding the genetic architecture of psoriasis which in turn highlight key biological pathways, some shared with other auto-immune diseases. Emerging evidence suggests that psoriasis is associated with risk of cardiovascular disease and other comorbidities. The true relationships between these conditions and determination of mechanisms will be important in the long-term management of psoriasis.

Building on the success of previous International Congresses held every three years since 1996, this 8th International Congress Psoriasis: from Gene to Clinic is designed to provide a forum for experts from around the world to present and discuss cutting edge issues.  Delegates are anticipated to be clinicians, scientists and members of the biotechnology and pharmaceutical industries.

To reflect the areas of current scientific and clinical interests, the meeting will concentrate on specific plenary topics: genes and pathogenesis; inflammation and immunity, comorbidites and targeted therapeutics.